Keyword: Novartis Oncology
Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.
Vas Narasimhan will take over as CEO of Novartis in February 2018 and will be inheriting several challenges, not the least of which is pricing pressure on both branded and generic drugs.
Cancer patient and advocate David Mitchell visited Novartis to discuss what a fair price might be for its CAR-T treatment, but he left disappointed.
One cancer patient is urging Novartis to weigh taxpayer investment in early-stage CAR-T science in setting a price on its new med tisagenlecleucel.
Novartis is adding jobs to its biologics manufacturing operations even as the Swiss company makes cuts across other parts of its global operations.